Literature DB >> 34049474

Berberine and Ginsenoside Rb1 Ameliorate Depression-Like Behavior in Diabetic Rats.

Jing-Hua Zhang1, Hui-Zeng Yang1, Hao Su2, Jun Song2, Yu Bai2, Lan Deng2, Chun-Peng Feng2, Hong-Xia Guo3, Yi Wang1, Xin Gao1, Yan Gu4, Zhong Zhen2, Yao Lu2.   

Abstract

Rhizoma coptidis (Huang-lian) and Asian ginseng have been widely used in the treatment of diabetes and other concurrent diseases with apparent effects. This study investigated the effects of the active ingredients of R. coptidis and ginseng, berberine and ginsenoside Rb1, on depression-like behavior in a rat diabetes model. The animal model was established via a high-fat diet and intraperitoneal injection of streptozotocin, while the animal's depression-like behavior was induced via chronic unpredictable mild stress. These experimental rats were divided into four groups: control, depression-like behavior (DLB), metformin plus fluoxetine hydrochloride (M+FH), and berberine plus ginsenoside Rb1 (B+GRb1) groups. Glucose metabolism and insulin resistance were evaluated by oral glucose test and glucose clamp study. Depression-like behavior was evaluated via behavioral analyses, including forced swim, sucrose preference, elevated plus maze, and open-field tests. HE and Nissl staining, plasma cortisol expression of adrenocorticotropic hormone, and brain-derived neurotrophic factor (BDNF) levels were assayed to explore the mechanisms of action. Compared with the control, rats in the DLB group had a significant increase in the levels of blood glucose and depression-like behavior. The B+GRb1 group significantly improved glucose metabolism and insulin resistance, reduced depression-like behavior, downregulated levels of plasma cortisol and adrenocorticotropic hormone under stress, and upregulated BDNF protein expression compared to the DLB rats. HE and Nissl staining data revealed that B+GRb1 protected neurons from pathological and morphological changes. Thus, berberine and ginsenoside Rb1 not only improved glucose metabolism in diabetic rats but also ameliorated their depression-like behavior under chronic unpredictable stress. Mechanistically, studied data with plasma hormonal levels and brain neuronal pathological/morphological changes supported the observed effects. The combination of berberine and ginsenoside Rb1 may have a clinical value in the management of diabetic patients with depression.

Entities:  

Keywords:  Behavioral Evaluation; Berberine; Brain-Derived Neurotrophic Factor; Coptis chinensis; Depression; Diabetes; Ginseng; Ginsenoside Rb1; Rhizoma coptidis

Year:  2021        PMID: 34049474     DOI: 10.1142/S0192415X21500579

Source DB:  PubMed          Journal:  Am J Chin Med        ISSN: 0192-415X            Impact factor:   4.667


  5 in total

1.  Antidepressant-Like Effect and Mechanism of Ginsenoside Rd on Rodent Models of Depression.

Authors:  Yu Li; Mei-Ling Wang; Bo Zhang; Xiao-Xu Fan; Qin Tang; Xue Yu; Li-Na Li; Ang-Ran Fan; Hong-Sheng Chang; Lan-Zhen Zhang
Journal:  Drug Des Devel Ther       Date:  2022-03-28       Impact factor: 4.162

Review 2.  Antidepressant Active Ingredients From Chinese Traditional Herb Panax Notoginseng: A Pharmacological Mechanism Review.

Authors:  Yanwei Li; Qingwan Guo; Junqing Huang; Ziying Wang
Journal:  Front Pharmacol       Date:  2022-06-16       Impact factor: 5.988

Review 3.  Antidepressant Potential of Quercetin and its Glycoside Derivatives: A Comprehensive Review and Update.

Authors:  Shen Chen; Yueheng Tang; Yang Gao; Kexin Nie; Hongzhan Wang; Hao Su; Zhi Wang; Fuer Lu; Wenya Huang; Hui Dong
Journal:  Front Pharmacol       Date:  2022-04-08       Impact factor: 5.988

Review 4.  Inhibition of Myocardial Cell Apoptosis Is Important Mechanism for Ginsenoside in the Limitation of Myocardial Ischemia/Reperfusion Injury.

Authors:  Zhihan Chen; Jingping Wu; Sijing Li; Caijiao Liu; Yulan Ren
Journal:  Front Pharmacol       Date:  2022-03-01       Impact factor: 5.810

5.  Apatinib and Ginsenoside-Rb1 Synergetically Control the Growth of Hypopharyngeal Carcinoma Cells.

Authors:  YanWei Li; Feng He; Yu Zhang; ZhanYu Pan
Journal:  Dis Markers       Date:  2022-01-13       Impact factor: 3.434

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.